觀點

2019中歐生物醫藥合作暨投融資大會 Sino-Euro BioPartnering (SEBP)

字號+ 作者:都市在線 來源:未知 2019-06-04 17:08 我要評論( )

活動時間 2019-06-14 至 2019-06-14 13:30-17:30 活動地點 上海 市徐匯區楓林路420號2樓,楓林國際創新中心。2F, No. 420, Fenglin Rd, Xuhui District, Shangh

活動時間

2019-06-14 至 2019-06-14 13:30-17:30

活動地點

上海市徐匯區楓林路420號2樓,楓林國際創新中心。2F, No. 420, Fenglin Rd, Xuhui District, Shanghai

組織單位

主辦單位:楓林集團(Fenglin Group)、捷邁生物醫藥咨詢有限公司(G-med Consulting)

承辦單位:楓林國際創新中心(Fenglin Biomedical Center)、上海聚科生物園區(Shanghai JUKE Biotech Park)

指導單位:徐匯區科學技術委員會

支持單位:岸金生物科技有限公司

項目簡介:

1.冷激光截骨手術機器人 (瑞士):

Cool Ablation Robot Laser Osteotomy (Switzerland)

This has now been achieved by AOT AG with the ground-breaking invention of the CARLO? system (Cold Ablation Robot-guided Laser Osteotome). This system allows for the direct collaboration of man and machine by means of a small, lightweight, and custom-designed tactile robotic arm, as well as navigation and control software and its corresponding hardware. All of these elements are combined in an ergonomic system, which fits easily into the operating room and allows the surgeon full control over this universal osteotomy device at any time. CARLO? is thus the worlds first medical, tactile robot that can cut bone without contact and with cold laser technology. The device allows the surgeon to perform bone operations with unprecedented precision, and in freely-defined, curved and functional sectional configurations, which are not achievable with conventional instruments.

AOT 公司發明了世界上第一個利用冷激光消融用于截骨手術的機器人。這是一項顛覆性發明。該系統通過一個小型、輕便和靈活的機械臂以及精準的導航和軟硬件控制系統直接將人和機器的協作完美結合,在手術室內能讓外科醫生隨時掌控這種通用的截骨裝置。該系統也是世界上第一款可以在不接觸骨組織的前提下使用冷激光技術切割骨骼的醫療機器人。該裝置允許外科醫生以前所未有的精度執行骨骼操作,并且具有自由定義的,彎曲的和功能性的截面配置,這是傳統儀器無法實現的。

2.治療性腫瘤疫苗 (瑞士)

Therapeutic vaccine technology (Switzerland)

Vaxeal is a private Europe-based biotech company, incorporated in 2009;

Headquartered in Vevey in Switzerland, with subsidiaries near Paris (FR) and London (UK). Vaxeal is proposing game-changing immunotherapies in the field of cancer and is a pioneer in the development of novel combinations of CD4+/CD8+ T-cell-based immunotherapies and Immune Checkpoint Inhibitor immunotherapies.

T-cell-based immunotherapies are today at center stage of new cancer treatments

(Science Magazine: “Breakthrough of the Year 2013); ASCO 2015; FDA/Novartis/Gilead 2017. VAXEAL completed pre-clinical trials of its first product, SVX-1 (combined Survivin T-cellbased LSPs/MAb anti-PD1 immunotherapy), on multiple animal and human cancer models, which shown great efficacy and no toxicity. Second candidate is already at advanced pre-clinical stage (Cyclin B1). Vaxeal expects to start clinical trials in Q3 2020. Regulatory fast track and special protocol assessment apply to each product.

私營公司Vaxeal成立于2009年,總部在瑞士沃韋,在法國巴黎和英國倫敦都設有分部。Vaxeal將帶來世界領先的顛覆性聯合腫瘤免疫療法,可同時激活CD4+和CD8+兩種T細胞并結合免疫檢查點抑制劑。T細胞免疫療法如今已成為腫瘤治療的焦點。Vaxeal已對其第一款產品,SVX-1(靶向生存素的T細胞抗原表達合成長肽+PD-1單抗的聯合免疫療法)在動物和人類癌癥模型上完成了臨床前試驗,驗證了效力和無毒性。第二款針對細胞周期蛋白Cyclin B1的候選藥物也已經在進行臨床前試驗。Vaxeal預計在2020年第三季度開始臨床試驗。兩款產品預計都將獲得監管機構快速通道和特殊評估協議。

3. NOTCH靶點腫瘤創新藥 創新 臨床一期 (瑞士)

NOTCH target anti-cancer new drug development (Switzerland)

Cellestia is a clinical stage biopharmaceutical company located in Basel and Lausanne, Switzerland, developing innovative first-in-class anti-cancer drugs. Our clinical stage lead compound CB-103 is an oral small molecule protein-protein interaction inhibitor, acting as selective oncogene tranion factor inhibitor providing personalized precision medicine for therapy of NOTCH positive cancers.

CB-103 combines exceptional potency, selectivity, safety and expectation of clinical efficacy based on previous NOTCH targeting agents, while overcoming the limitations of these due to its unique Mode of Action. The development is complemented by a diagnostic program for patient selection.

Cellestia是一家專注抗腫瘤一線新藥的生物公司,坐落于巴塞爾和洛桑。公司的旗艦化合物CB-103口服蛋白相互作用小分子抑制劑已進入臨床階段,可對轉錄因子類癌基因進行選擇性抑制,為NOTCH陽性的癌癥提供個性化精準治療。與前代針對NOTCH的靶向藥相比,CB-103結合了出眾的藥力、特異性、安全性和預計臨床療效,并以獨特的作用方式克服了前代靶向藥的不足。該公司還有一套輔助藥物研發的診斷方案以選擇合適的病人。

4. 創新藥治療心力衰竭和免疫性疾病 臨床二期 (美國)

New drug to treat heart failure, phase II, (US)

Serpin Pharma has developed a synthetic peptide, SP16, derived from a naturally occurring serine protease inhibitor (SERPIN) containing a unique anti-inflammatory core motif that targets a key immune regulating receptor, LRP1 (Low-density lipoprotein receptor–related protein-1). The anti-inflammatory and immunomodulatory effects of the peptide have been demonstrated in a variety of auto-immune and acute inflammatory diseases and prominently used in the lead indication acute myocardial infarction (AMI), where treatment with SP16 protects cardiac tissue, reduces infarct size and restores heart function. SP16 is approved by the FDA to proceed to human clinical trials for AMI.

Serpin Pharma開發了一種合成肽,名為SP16。 SP16來源于一種天然存在的絲氨酸蛋白酶抑制劑(SERPIN),含有獨特的抗炎核心基序,靶向作用于一種關鍵的免疫調節受體LRP1(低密度脂蛋白受體相關蛋白-1)。這種肽的抗炎和免疫調節作用已在多種自身免疫和急性炎癥性疾病中得到證實。運用SP16治療突發性急性心肌梗死(AMI)可保護心臟組織,減少梗死面積和恢復心臟功能。 SP16已被FDA批準進行急性心肌梗死的人體臨床試驗。

5. 腫瘤抗體藥物 臨床前, 一年左右進入臨床一期 (美國)

New antibody drug to treat cancer, pre-clinical needs one year to enter Phase I (US)

A US based company develops a new antibody drug to treat cancer. The candidate is still in pre-clinical stage and will need one year to enter clinical stage in the US. The company strong management team and received investment from the America Cancer Research Foundation. The company will develop a number of antibody assets and is now seeking investment partner as well as manufacturer from China.

該美國公司開發了一種治療癌癥的新型抗體藥物。此候選藥物仍處于臨床前研究階段,大概需要一年時間才能進入美國的臨床階段。 公司有強大的管理團隊,現已獲得了美國癌癥研究基金會的投資。 該公司將繼續開發抗體藥物資產,目前正在尋求中國的投資合作伙伴和制造商。

6. 新一代滅菌器械 (愛爾蘭)

Innovative disinfection equipment (Ireland)

Novaerus uses a patented atmospheric plasma discharge of the dielectric barrier discharge type. The plasma discharge comprises electrons and ions that cause extensive damage to microorganisms. Unlike other products, microorganisms are exposed directly to the plasma discharge as opposed to by-products of the discharge.

Novaerus portable units are highly effective in any situation with an ongoing need to safely reduce pathogens, mitigate odours, and neutralise environmental contaminants in indoor air.

Novaerus公司運用受專利保護的介質阻擋放電技術生成大氣等離子體,生成的等離子體包括電子和離子,能廣泛殺死微生物。與其他產品不同,微生物直接暴露于等離子體下而不是等離子體發射的伴隨產物下。

Novaerus便攜式設備在任何需要安全減少病原體、減輕氣味和消除室內空氣污染物的場合下都非常有效。

7.手部衛生系統和掃描儀

Hand hygiene system and scanner

Background:

An award-winning life science and medical device company has created a patented hand hygiene system and scanner as a unique automation solution that provides objective and continuous hand hygiene monitoring.

Technology highlights:

1. The hand hygiene system consists of a scanner, electronic monitoring equipment, and a cloud-based monitoring/reporting system for immediate assessment of hand rubbing technique. It uses software-based objective feedback to match personalized RFID card-based user identification.

2. It is compatible with most hospital information systems (ensuring data privacy) and has a fully customizable reporting system.

3. The hand hygiene system will save time, effort and money for hospital training staff. Employee hand hygiene is an effective way to prevent hospital-acquired infections (HAI).

4. Rapidly improve the quality and compliance of hand hygiene for clinical staff and hospital staff.

5. Track hand hygiene quality in real time for ease of management.

6. The hand hygiene system is currently sold in 20 countries in North America, Europe, and Asia. Reference materials from leading academic health centers and WHO-affiliated hand hygiene experts are available upon request. The system is supported by more than 20 peer-reviewed articles and publications.

7. The scanner and the adjacent cloud-based reporting system can be rented monthly or purchased directly as a complete system.

背景:

一家屢獲殊榮的生命科學和醫療設備公司。我們創造了專利技術的手部衛生系統和掃描儀,作為一種獨特的自動化解決方案,提供客觀和持續的手部衛生監測。

技術特點:

1. 其手部衛生系統由掃描儀,電子監控設備和基于云的監測/報告系統組成,可立即評估手部摩擦技術。它使用基于軟件的客觀反饋,與個性化的基于RFID卡的用戶識別相匹配。

2. 它與大多數醫院信息系統兼容(確保數據隱私),并具有完全可定制的報告系統。

3. 手部衛生系統將為醫院培訓員工節省時間,精力和金錢。員工手部衛生是預防醫院獲得性感染(HAI)的 有效方法。

4. 迅速提高臨床工作人員和醫院工作人員的手部衛生質量和合規性。

5. 實時跟蹤手部衛生質量以便管理。

6. 其手部衛生系統目前在北美,歐洲和亞洲的20個國家銷售?筛鶕筇峁╊I先的學術保健中心和世衛組織附屬手部衛生專家的參考資料。它得到了20多篇同行評審文章和出版物的支持。

7. 掃描儀和相鄰的基于云的報告系統可作為月租,或者可以購買完整的系統。

8.瑞士磁性血液凈化技術設備研發公司

Magnetic blood purification equipment R&D company (Switzerland)

Background:

The company has an award-winning patent for an innovative blood purification technology which provides a new approach to specific blood purification in intensive care units. Blood is pumped through an extracorporeal circuit, and nanoscale magnetic adsorbents are added. The adsorbents combine with the target substance in the blood through specific binding sites and are then removed by magnetic force. The purified blood is then transported back to the patient's body.

Technology highlights:

1. Compared with traditional blood purification methods, the company's patented technology can remove large targets, selectively adsorb disease-related compounds including bacteria, endotoxins, cytokines, and break the inflammatory cascade. Purified blood can be completely recovered through adsorbents.

2. Blood coagulation utilizes magnetic nanoadsorbents that can be covalently equipped with a specific binding agent to capture the target compound.

3. The physical limits of conventional blood purification methods in terms of target size, selectivity, and mass transfer can be overcome by engineering nanoscale adsorbent materials.

4. The core of the system is made of iron carbide, whose magnetization is 2-3 times higher than iron oxide nanoparticles and is used for most magnetic separations on laboratory scales.

5. High magnetization can be used to recover the nanoadsorbents completely and rapidly at the relevant flow rate for blood purification. This is critical for therapeutic applications in the extracorporeal blood loop, where the highest separation efficiency minimizes the potential risk of internal nanoadsurbents exposure to patients.

6. The company has global licenses for patents including magnetic core manufacturing and functionalization in the field of blood purification.

7. The solution stabilizes septic shock, shortens the hospital stay in the ICU, improves survival rate and greatly reduces medical costs.

背景:

一家致力于創新的專利獲獎血液凈化技術研發公司,專利血液凈化技術為重癥監護病房的特定血液凈化提供了一種全新的方法。將血液泵送通過體外回路并添加納米級磁性吸附劑。它們通過特異性結合位點與靶物質結合,通過磁力回收后凈化的血液再輸送回病患身體里。

技術特點:

1. 與傳統血液凈化手段相比,標的公司的專利技術可以去除大目標,有選擇性去除疾病相關化合物 包括細菌,內毒素,細胞因子,打破炎癥級聯,純化的血液可以完全吸附劑回收。

2. 血液凝固利用磁性納米吸附劑,其可以共價配備特異性結合劑以捕獲目標化合物。

3. 通過工程納米級吸附劑材料可以克服常規血液凈化方法在目標大小,選擇性和質量傳遞方面的物理限。

4. 系統核心由碳化鐵制成,與氧化鐵納米粒子相比,它的磁性強度高出2-3倍,用于實驗室規模的大多數磁性分離。

5. 高磁化強度可以在相關的流速下快速,完整地回收納米吸附劑,用于血液凈化。這對于體外血液回路中 的治療應用至關重要,其中最高的分離效率使內部納米吸附劑暴露于患者的潛在風險最小化。

6. 擁有包括血液凈化領域磁芯制造和功能化的等專利的全球許可。

7. 解決方案穩定感染性休克,縮短ICU的住院時間,提高存活率同時極大的降低醫療成本。

9.腦神經調節治療系統研發制造公司

Neuromodulation therapy system R&D Company

Background:

The company has developed a product which provides focal nerves stimulation for the six branches of the occipital and trigeminal nerves to reach the brainstem. It simultaneously affects the higher centers of the brain, which are involved in controlling and regulating pain and mood. The release of anti-nociceptive neurotransmitters, such as norepinephrine and serotonin, inhibits pain and improves mood. It can be used to treat diseases such as migraine, depression, ADHD, and insomnia.

Technology highlights:

1. The product is the world's first and only adaptive multi-channel neuromodulation system.

2. Lightweight, easy to carry, convenient for home use; low cost of treatment; real-time monitoring; artificial intelligence data analysis; simplified treatment process and reduced treatment costs.

3. The product is connected to an artificial intelligence algorithm based on big data on the cloud, in order to provide data collection, analysis and adjustment for customized treatment.

4. According to clinical data at Yale University School of Medicine, Hartford Healthcare Headache Center, Dartmouth–Hitchcock Medical Center and other flagship hospitals, 76% of patients had significantly reduced pain after using this product for 1 hour, while only 31.6% of patients reported pain reduction under traditional therapy for chronic and sporadic migraine.

5. 90% of patients with depression achieved a rapid and significant reduction in depression scores within 6 weeks of treatment at home.

6. Electronic, flexible payment methods.

背景:

通過為枕骨和三叉神經的六個分支提供局灶性神經刺激到達腦干,同時影響大腦中較高的中樞,這些中心參與控制和調節疼痛和情緒。釋放抗傷害性神經遞質,如去甲腎上腺素和5-羥色胺,可抑制疼痛,改善情緒。用于治療偏頭痛,抑郁,多動癥,失眠等疾病。

技術特點:

1. 產品為全球第一個并且唯一的自適應多通道神經調節系統產品。

2. 輕巧,便于攜帶,方便在家使用;治療費用低;隨時監控;人工智能數據分析;簡化治療的過程和降低治療費用。

3. 產品連接云端大數據人工智能算法,進行數據收集,分析,調整提供定制化治療。

4. 經過美國耶魯大學醫學院,哈特福德醫療保健頭痛中心,Dartmouth–Hitchcock醫療中心等權威醫院 臨床使用,證明76%的病人在使用1小時后疼痛明顯減少,傳統用于治療慢性和偶發性偏頭痛的方法只有31.6%的病人有疼痛減少的反饋。

5. 90%的抑郁癥患者在家治療的6周內抑郁癥分數實現了快速并明顯的降低。

6. 電子化,靈活的付費方式。

10.智能可穿戴醫療設備研發公司

Intelligent wearable medical device R&D company

Background:

A leading wearable physiological monitoring company committed to actively promoting the commercialization of healthcare. Inspired by first-class products in the consumer sector, the company provides solutions that combine medical-grade quality and reliability with ease of use and design. Its digital health solutions enable users to maintain a healthy lifestyle and improve healthcare outcomes, with the goal of reducing the cost of medical expenses. Its wearable solutions have received numerous international awards and high-quality recognition, and the management team is known worldwide for its expertise in wearable monitoring.

Technology highlights:

1. The global wearable market is expected to reach $18.9 billion in 2020, while AI+ medicine market is expected to reach $36 billion in 2025.

2. The company has 15 patents in the key fields of multi-sensor and physiological monitoring of body fatigue.

3. The product provides management and application of daily physiological health monitoring, postoperative real-time monitoring, occupational health monitoring, and other aspects.

4. The profit model is product hardware sales + ecosystem usage subion/sharing + third-party data usage/analysis.

5. The open platform can incorporate the health analysis data of the third party.

6. Monitored indicators: heart rate, blood oxygen, skin temperature, perfusion index, respiratory rate, heart rate variability, heartbeat interval, exercise pace, stress, sleep, blood pulse, energy expenditure, sweat, health score, skin moisture, glucose trend.

背景:

一家領先的可穿戴生理監測公司。積極推動醫療保健的消費化,提供將醫療級質量和可靠性與易用性和設計相結合的解決方案,其靈感來自消費者領域的一流產品。他的數字健康解決方案支持用戶保持健康的生活方式,改善醫療保健治療效果,旨在減少醫療費用的成本負擔。其可穿戴解決方案已獲得多項國際獎項和高質量認可,管理團隊因其在可穿戴監控方面的專業知識而享譽全球。

技術特點:

1. 全球可穿戴市場預計2020年達到189億美元的規模,全球醫療人工智能2025年預計為360億美元。

2. 標的公司在多傳感器,身體磨損生理監測的關鍵領域擁有15個專利系列。

3. 產品提供了日常生理健康監測,術后實時監控,職業健康監測等方面的管理和應用。

4. 盈利模式為產品硬件銷售+生態系統使用訂閱/分享+第三方數據使用/分析。

5. 開放式平臺可以引進第三方機構的健康分析數據。

6. 監測指標:心率,血氧,皮膚溫度,血流灌注指數,呼吸頻率,心率變異性,心心跳間隔,運動步伐,壓力,睡眠,血脈沖波, 能量消耗,流汗,健康評分,皮膚水分,葡萄糖趨勢。

11.制藥技術研發公司

Pharmaceutical technology R&D company

Background:

An innovative pharmaceutical development company has a proprietary technology to improve the properties of pharmaceutical products. The company can produce new crystalline and particulate forms for existing compounds, significantly improving clinical efficacy. The company has technology platforms for both small and large molecules, which can optimize processes for a variety of drug dosage forms (e.g. oral, inhalation, nasal, subcutaneous injection or sublingual administration).

Technology highlights:

1. Solutions for particle formation, formulation and process engineering catered to the global pharmaceutical and health supplement industry;

2. Ongoing development for proprietary products targeting unmet clinical needs, including female health, urinary and respiratory diseases;

3. Crystallization and particulate engineering technology based on supercritical fluid;

4. Process improvement to increase clinical efficacy, e.g. crystal polymorphic form control, insoluble drug, inhaled drug, stabilization of large molecules.

5. Resolving challenges associated with drug development (partnership with 13 of global top 20 companies)

6. Proprietary technology to develop own pipeline

7. A highly-efficient, stable and scalable pharmaceutical production process for proprietary drug delivery approved by the regulatory body. The platform is expected to create unique opportunities for improving clinical efficacy and improving the quality of life of patients.

背景:

是一家制藥技術的創新技術公司,該公司使用專有技術,改善藥物性能?梢越Y晶出藥物的新晶型, 制備新型的藥物微粒,從而極大地提高其臨床療效。同時擁有適用于小分子和大分子的技術支持平臺,可優化一系列藥物劑型(例如,口服、吸入、鼻腔,皮下注射,舌下含服給藥等)

技術特點:

1. 服務于全球制藥與保健行業,解決藥物微粒的形成、制劑和生產工藝中的難題。

2. 開發自主創新產品,定位于未滿足的臨床需求和一些重要領域,包括女性健康、泌尿疾病和呼吸系統疾病等。

3. 基于超臨界流體的結晶和微粒工程技術。

4. 提高藥物的治療效果,例如晶型控制、難溶藥、吸入 給藥、大分子藥物穩定性。

5. 解決藥物產品開發的挑戰(與全球20強企業中的13家有合作)。

6. 利用專有技術優勢開發自主立項產品。

7. 專有的給藥技術是一種高效、穩定,完全可放大的藥物生產工藝,并得到了藥監部門的認可。其技術平臺可為改善藥物臨床給藥性能創造獨特機會,以提高廣大患者的生活質量。

12. 西班牙泌尿系統疾病數字診斷治療

Digital diagnosis and treatment for urinary diseases (Spain)

Background:

Established in 2012 as the world’s first digital diagnosis and treatment company for urinary diseases, the company has an innovative digital treatment platform based on urine pH management, enabling real-time tracking for pH-related urinary diseases. The company owns 9 inventions and 49 patents for diagnosis and treatment of kidney stones, and has an electronic IVD device transferring real-time data to software platforms contained in electronic devices such as mobile phones, providing patients with timely personalized information, including health warnings, metabolic assessment, urine data, dietary/lifestyle recommendations, and meanwhile offering 3 dietary supplements for urine pH adjustments. The system can allow sharing and tracking of patient data by hospitals and insurance companies, allowing for greater patient participation, improved clinical outcome, more timely treatment feedback and overall better patient experience.

Technology highlights:

1. In 2020, Chinese digital healthcare market is expected to reach $110 billion USD, while around the globe the gross market size is estimated to reach $536.6 billion USD.

2. Kidney stone has an increasing prevalence in China especially among the young and the middle-aged because of an increase in the diabetic and obese population. According to statistics, the incidence of kidney stone has increased by 70% in the past 15 years in the US. Kidney stone is usually a life-long disease which easily relapses. It is also the most expensive urological disease in the US. There are about 700 million kidney stone patients worldwide.

3. Real-time monitoring, as well as timely dietary and lifestyle interventions are very important to prevent relapses.

4. The company has a first-class digital urological treatment platform to improve clinical outcomes and reduce the costs associated with kidney medication. It also helps the diagnosis of kidney stone and other urinary tract diseases by performing tests and controlling patients’ urine pH,

5. The company has received CE marking, ISO13485, ISO9001 and has been certified by AEMPS (Spanish Agency of Medicines and Medical Devices).

6. 9 inventions, 49 patents, 6 clinical trials involving 500+ patients from 20 hospitals, with endorsements from internationally famous key opinion leaders.

7. Flexible and multi-channel recurrent revenue business model, with income from devices, dietary supplements, and subion services.

8. Expected revenue in 2023: EUR 30 million per year, with 40% of EBITA and 15% compound annual growth rate.

背景:

標的公司成立于2012年,是泌尿系統第一個數字診斷治療的公司。其創新的基于尿液pH值管理的數字治療平臺,可以實 時跟蹤診斷PH值相關的泌尿系統疾病。針對腎結石的診斷和治療,擁有9項發明,49項專利。已推出 IVD 電子體外診斷器械,數據通過藍牙實時傳輸至手機等電子設備的軟件平臺,及時提供患者的個性化信息服務,包括健康警告,新陳代謝評估,尿液數據,飲食/生活方式推薦,同時提供尿液PH值調節管理的三種醫療食品。系統可與醫院/保險公司等實現患者數 據信息共享和跟蹤,實現更高的患者參與度,更加的治療效果,更及時的醫療反饋和更好的患者體驗。

技術特點:

1. 2020中國數字醫療市場預計達到1100億美元,全球數字醫療市場規模將達5366億美元。

2. 腎結石在中國的發病率逐年升高,患者以青壯年為主。由于糖尿病、肥胖人群不斷增加,腎結石的發病率不斷提高。據統計美國在過去15年里患病率增加70%,易復發,通常是一種終生性疾病。在美國腎結石是泌尿外科最昂貴的疾病。全球7億腎結石病患。

3. 實時監控,并且及時調整飲食方式和生活方式對預防復發非常重要。

4. 標的公司的解決方案是泌尿外科的一流數字治療平臺,以改善臨床結果并降低與腎臟藥物治療相關的成本,通過自主測試、管理尿液的pH 值診斷腎結石和其他泌尿系統疾病。

5. CE認證,ISO13485, ISO9001, AEMPS 認證。

6. 9項發明,49項專利 ,20家醫院500+患者的6個臨床,國際知名意見領袖的站臺背書。

7. 靈活多樣經常性性營收商業模式:器材+醫療食品+服務訂閱。

8. 2023年預計實現3千萬歐元年營收,40%EBITA,15%年復合增長率。

13.德國女性可穿戴生理檢測

Female wearable physiology device (Germany)

Background:

1. The company is dedicated to developing wearable sensing solutions for physiological monitoring and bringing the solution to clinical trials. The company has transferred medical technology into regulatory-approved diagnostic tools, which combines sensor-based measuring device and algorithm-based intelligent assessment software to continuously search and analyze biomarkers in a telemedicine platform, in order to realize more successful and cost-effective treatment while satisfying medical needs

2. The company has developed an electronic sanitary device providing solutions for the coverage and analysis of the entire menstrual cycle for the first time. The product consists of a flexible plastic ring containing a biosensor that can stay in the vagina for as long as 30 days without being felt. The device allows for automatic measurement of body core temperature every 5 minutes and can be combined with processing software, the data can be uploaded and assessed by an algorithm which analyzes the reproductive health patterns, and the results can be visualized on a computer or mobile device.

Technology highlight:

1. The global market size for female health is expected to exceed 50 billion USD in 2025.

2. More than 70% of women of childbearing age on contraception pills have increasing demand on hormone-free contraception methods;

3. The company has a product and digital diagnostic platform which combines sensor-based wearable devices with intelligent medical algorithm-based evaluation software to detect and analyze fertility/pregnancy patterns.

4. Identifying individual reproductive health patterns and improve the success rate of fertility treatment, while reducing the number of visits, cost, and side-effects.

5. Individualized, more successful fertility and gynecological treatment reducing cost and side-effects

6. Easy-to-use, hormone-free safe contraception

7. Determine pregnancy patterns to ensure pregnancy health and prevent premature delivery

8. Ce-marked medical device and telemedicine platform enabling remote monitoring, and individualized and more effective treatment

9. Reliability of ovulation test is >99%; accuracy of fertilization is 88.8%

10. No hormones or plasticizers.

11. Suitable for across the menstrual cycle and all lifestyles.

12. Profit mode: product sales and subion service (B2B2BC & B2C)

13. Expected revenue in 2023: EUR 86 million, 32% EBIT.

背景:

1. 一家專注從事可穿戴傳感器生理監測解決方案的研究和臨床試驗的研發公司。公司將醫療技術轉移到監管認可的診斷工具中,結合基于傳感器的測量設備和基于醫療算法的智能評估軟件在遠程醫療平臺內搜集分析用于檢測連續測量的生物數據中的各個生物標記模式,滿足醫療需求同時實現更成功,更具成本效益的治療方法。

2. 其女性生理周期監控產品是一種電子衛生保健解決方案,能夠首次映射和分析整個周期。該產品由一個柔性塑料環組成,該塑料環裝有放置在陰道內的生物傳感器。它在那里停留長達30天,女人無法感覺到。它可在整個循環中每 5分鐘自動測量身體核心溫度,從而可連續測量身體核心溫度(BCT)。利用閱讀設備和移動軟件,數據被上傳并評估醫療算法,檢測生育模式。結果顯示在計算機或移動設備的儀表板上。

技技術特點:

1. 2025年全球女性健康市場估計價值超過500億美元

2. 應用避孕藥的70%+的育齡女性對對無激素方法的避孕需求不斷增長

3. 標的公司推出的產品和數字診斷平臺將基于傳感器的可穿戴設備與基于智能醫療算法的評估軟件相結合,檢測和分析生育/妊娠模式。

4. 確定個體生育模式,使個體化生育治療成功率提高,成本和副作用降低。

5. 實現個性化,更成功的生育治療和婦科治療,減少數量,成本和副作用。

6. 簡單易用,安全避孕,不含激素。

7. 確定懷孕模式,以確保懷孕健康和預防早產。

8. CE認證的醫療設備和遠程醫療平臺,可實現遠程患者監護和個性化,更有效的治療。

9. 臨床排卵檢測的可靠性>99%,預測受精期的準確度為88.8%。

10. 產品不含激素和增塑劑。

11. 適用于所有生理周期和生活方式。

12. 盈利模式:產品銷售+服務訂閱 (B2B2BC & B2C)。

13. 預計2023年實現8千6百萬歐元營收,32% EBIT。

報名點擊鏈接進入:http://www.95work.com/jkwx-service/1097860?uuid=a7c855c5-699f-4594-bf3c-fa6f0464317b&from=timeline&isappinstalled=0

----分隔線----東方都市網----分隔線----投稿:975981118@qq.com 歡迎投稿
東方都市網,上海東方都市網,,東方都市網,財經頻道站http://www.marocmaths.com
上海計晨傳媒旗下媒體:【今日早報網、上海東方都市網、上海都市網、中國糖酒新聞網、中視快報網、新華財經在線】 上海媒體推廣、新聞發布、現場采訪、會務直播、活動發布聯系計晨,低價服務好。

免責聲明:

自媒體綜合提供的內容均源自自媒體,版權歸原作者所有,轉載請聯系原作者并獲許可。文章觀點僅代表作者本人,不代表本網立場。 對本文內容、觀點保持中立,不對內容的準確性、可靠性或完整性提供任何明示或暗示的保證。

相關文章
  • 文博會-2019中國文化和旅游融合發展論壇在北京召開

    文博會-2019中國文化和旅游融合發展論壇在北京召開

    2019-06-04 09:30

  • 2019第三方電子招投標平臺商業模式的探討高峰論壇

    2019第三方電子招投標平臺商業模式的探討高峰論壇

    2019-06-03 12:26

  • Harbor House2019初夏甄選,理想生活狂歡季

    Harbor House2019初夏甄選,理想生活狂歡季

    2019-05-31 16:38

  • 色彩未來丨2019上海廚衛展帝朗衛浴開創衛浴定制新風潮

    色彩未來丨2019上海廚衛展帝朗衛浴開創衛浴定制新風潮

    2019-05-31 10:55

網友點評